Search 

PressCise is a research project from CHalmers and University of Gothenburg aimed at developing a unique bandage. The bandage will be used for remediation including varicose vein surgery and should be easy to wrap.

Recopharma is a biotechnology company, founded in 2004. The company is based in Gothenburg, Sweden, at the Biotech Center.

Recopharma carries out activities in the field of ophthalmology, developing potential products for treatment of eye diseases. The Company has developed a unique technology, with many potential applications,  that uses mucins, which naturally occur in lacrimal fluid, where they protect, lubricate and help keep the tear film intact.

SPAGO Imaging conducts research and development in the nanomedicine field with focus on diagnosis and treatment of cancer. The development is based on SPAGO's two proprietary platform technologies, IonXgel and 3PEG.

IonXgel is a unique nanomaterial and the basis for SPAGO’s novel cancer selective MRI contrast agent, SPAGO Pix. The SPAGO Pix portfolio also includes opportunities within cancer selective drug delivery for improved cancer treatment, as well as additional MR imaging indications. 

3PEG is a proprietary pegylation platform that can improve critical drug properties of small molecules, peptides and proteins, and provide e.g. increased efficacy and reduced side effects, and has therefore a broad clinical application.

SPAGO Imaging encompasses many years of experience from contrast- and pharma industry, including discovery research, early clinical- and business development.

The company was established in 2007 and is located in Lund, Sweden and employs a team of eight. SPAGO Imaging is publicly traded on the “Aktietorget” exchange in Stockholm.

TikoMed is a specialty biopharmaceutical company founded in a cradle of fierce entrepreneurship, cutting edge science and industrial competence. 

"TikoMed is developing and commercializing life-saving products for severe diseases" 

We apply advances in innate immunology to identify mechanisms and develop new products.

Our mission is to develop and commercialize innovative treatments for severe and life-threatening diseases, for the benefit of patients, who lack satisfactory treatment options.